| This week's sponsor is FierceBiotech Drug Development Forum. | |  | 1 Week Left to Register & Attend - FierceBiotech 2nd Drug Development Forum
Network with 300+ biotech leaders and 100+ executive-level speakers at the largest biotech conference for optimizing pipeline strategies, partnerships and deal making September 25-27 in Boston, MA. Sign up today & save 15% w/ code C942FIERCE. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Tuesday, September 19, 2017 Ahead of generic competition for its top-selling Advair, GlaxoSmithKline nabbed an FDA approval for the "closed-triple" COPD therapy Trelegy Ellipta. It's the latest addition to GSK's lung-med lineup—and it's expected to kick in blockbuster sales. |
|
|
Top Stories Of The Week Wednesday, September 20, 2017 A phase 3 trial of Alnylam’s patisiran has hit all of its primary and secondary endpoints. The clean sweep is a big win for Alnylam and the Sanofi-partnered gene silencing drug, which is now set to be put before regulators around the end of the year. Thursday, September 21, 2017 Rumors that Amazon is looking to parachute into the drug field are getting louder. Amazon is already in talks with pharmacy benefits managers, an analyst reports, and that poses a larger threat to the pharma industry than some might realize. Tuesday, September 19, 2017 Sir Andrew Witty has joined Hatteras Venture Partners. The former GlaxoSmithKline CEO is taking up a venture partner position at the VC shop, setting him up to offer advice on the positioning of its portfolio companies. Friday, September 15, 2017 LISBON, Portugal—Drugmaker after drugmaker has touted data showing next-gen diabetes meds lower hypoglycemia risks—and new studies from Novo Nordisk show why. Type 2 diabetes patients who suffer severe hypoglycemia are four times more likely to die within 15 days—and twice as likely to die, period. Wednesday, September 20, 2017 Optinose has filed to raise $100 million in an IPO. The filing comes days after the FDA approved the intranasal delivery specialist’s treatment for nasal polyps, the commercialization of which will be the focus of a post-IPO spending spree. Tuesday, September 19, 2017 The vacant Novartis manufacturing facility in Suffern, New York, that had been on the auction block for more than two years was sold for $18 million to a buyer who turned around and resold the property to a Manhattan-based developer for $30 million. Wednesday, September 20, 2017 When it comes to combating HIV, three virus-killing antibodies should be better than one, scientists at French pharma giant Sanofi have long believed. Now they have compelling preclinical evidence that the approach might work, not only to prevent the virus that causes AIDS in healthy people, but also to treat patients facing the risk of developing resistance to current antiretroviral treatments. Tuesday, September 19, 2017 After deadly outbreaks that caught scientists and providers off guard, vaccine experts may be happy to see Johnson & Johnson and a U.S. development agency collaborate on pandemic flu. In a novel agreement, they've paired up to focus on a vaccine program and potential flu drugs from J&J. Thursday, September 21, 2017 The new "Vant" added to the Vivek Ramaswamy family, with its aim of improving trials with artificial intelligence, announced its new CEO this week. Resources Presented By: Ashfield Healthcare Join this webinar to learn how to design, deliver, and measure a successful patient support program. Presented by Nareda Mills, Ashfield's SVP of Patient Services in the US, you’ll discover how to improve adherence and improve patient outcomes using 5 key methods. |
|
